If approved, MCO-010 would be the first treatment to restore vision in legally blind RP patients without needing genetic ...

Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene ...

Nanoscope’s BLA has been granted rolling review by the FDA, with the first modules already submitted. The completion of the ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutationCELESTE is informed by the STELLA prospective ...

Stargardt disease, the leading form of juvenile macular degeneration, results in progressive vision loss due to retinal damage. The global Stargardt disease market is growing, driven by the rising ...

Researchers link early cone dysfunction in RPGR-related retinal dystrophy to high myopia, with timing of degeneration ...

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

DALLAS, TX, USA I July 14, 2025 I Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic ...

These are exciting times for biotech business Complement Therapeutics, which stands on the cusp of an important milestone in ...

Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...